Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of casirivimab and imdevimab in Japanese adult volunteers
jRCT2071200117Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of casirivimab and imdevimab in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability and Pharmacokinetics of casirivimab and imdevimab. Started Mar 2021; status: completed.
02
Drugs
casirivimabimdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071200117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200117.